Fairmount Funds Management LLC Purchases Shares of 1,962,953 Scholar Rock Holding Co. (NASDAQ:SRRK)

Fairmount Funds Management LLC bought a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,962,953 shares of the company's stock, valued at approximately $84,839,000. Scholar Rock accounts for 8.4% of Fairmount Funds Management LLC's investment portfolio, making the stock its 5th biggest holding. Fairmount Funds Management LLC owned approximately 2.10% of Scholar Rock as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of SRRK. Barclays PLC raised its stake in Scholar Rock by 103.4% in the 3rd quarter. Barclays PLC now owns 165,449 shares of the company's stock valued at $1,324,000 after purchasing an additional 84,118 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Scholar Rock by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock worth $310,000 after buying an additional 379 shares in the last quarter. GAMMA Investing LLC boosted its position in Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after acquiring an additional 269 shares during the last quarter. Hamilton Lane Advisors LLC purchased a new stake in Scholar Rock during the 4th quarter valued at about $1,274,000. Finally, Nisa Investment Advisors LLC raised its holdings in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after acquiring an additional 1,031 shares during the last quarter. Hedge funds and other institutional investors own 91.08% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wedbush reissued an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $42.67.

Scholar Rock Trading Down 0.5 %

Scholar Rock stock traded down $0.14 during mid-day trading on Friday, hitting $30.85. The company's stock had a trading volume of 846,155 shares, compared to its average volume of 1,268,790. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $2.93 billion, a PE ratio of -13.13 and a beta of 0.37. The stock's fifty day moving average is $31.63 and its two-hundred day moving average is $35.87.

Insider Transactions at Scholar Rock

In related news, insider Tracey Sacco sold 5,000 shares of Scholar Rock stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $32.83, for a total value of $164,150.00. Following the completion of the sale, the insider now owns 71,750 shares in the company, valued at approximately $2,355,552.50. This trade represents a 6.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Edward H. Myles sold 142,292 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the transaction, the chief financial officer now owns 111,345 shares in the company, valued at $3,966,108.90. This trade represents a 56.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 255,231 shares of company stock worth $9,220,236. 13.30% of the stock is currently owned by company insiders.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.